AE-Jardiance-Logo

Prof-merlin-keyfact1.png

reduced risk of CV death
or kidney disease progression*1,2

Prof-merlin-keyfact2.png

reduced risk of CV death
or hospitalisation for heart failure†3,4

Prof-merlin-keyfact3.png

reduced risk of CV death‡5

Prof. Christoph Wanner - For you as a nephrologist in your daily practice, what is the most impactful outcome that was shown in the EMPA-KIDNEY¹ trial?

RELATED CONTENT